Nuclear oxidative damage correlates with poor survival in colorectal cancer

por Sheridan, J, Wang, L-M, Tosetto, M, Sheahan, K, Hyland, J, Fennelly, D, O'Donoghue, D, Mulcahy, H, O'Sullivan, J
Publicado 2009

Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive

por O'Toole, A, Michielsen, A J, Nolan, B, Tosetto, M, Sheahan, K, Mulcahy, H E, Winter, D C, Hyland, J M, O'Connell, P R, Fennelly, D, O'Donoghue, D, O'Sullivan, J, Doherty, G A, Ryan, E J
Publicado 2014

Effects of CDX2 on prognosis and chemotherapy responsiveness in mismatch repair‐deficient colorectal cancer

por Ryan, É. J., Creavin, B., Khaw, Y. L., Kelly, M. E., Mohan, H. M., Geraghty, R., Ryan, E. J., Kennelly, R., Hanly, A., Martin, S. T., Fennelly, D., McDermott, R., Gibbons, D., O'Connell, P. R, Sheahan, K., Winter, D. C.
Publicado 2018

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

por Schoemaker, N E, Kuppens, I E L M, Moiseyenko, V, Glimelius, B, Kjaer, M, Starkhammer, H, Richel, D J, Smaaland, R, Bertelsen, K, Poulsen, J P, Voznyi, E, Norum, J, Fennelly, D, Tveit, K M, Garin, A, Gruia, G, Mourier, A, Sibaud, D, Lefebvre, P, Beijnen, J H, Schellens, J H M, ten Bokkel Huinink, W W
Publicado 2004